Role of Wnt signaling in tissue fibrosis, lessons from skeletal muscle and kidney

Current Molecular Medicine

Volumn 14, Issue 4, 2014, Pages 510-522

  Cisternas, P ^a   Vio, C P ^a   Inestrosa, N C ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

Fibrosis disease; Kidney diseases; Skeletal muscle; Wnt signaling

Indexed keywords

ANGIOTENSIN II; CONNECTIVE TISSUE GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA;

EXTRACELLULAR MATRIX; FIBROSIS; GENE OVEREXPRESSION; HUMAN; KIDNEY DISEASE; MACROPHAGE; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; WNT SIGNALING PATHWAY; ANIMAL; KIDNEY; METABOLISM; PATHOLOGY;

ANIMALS; FIBROSIS; HUMANS; KIDNEY; MUSCLE, SKELETAL; WNT SIGNALING PATHWAY;

EID: 84904046471     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/1566524014666140414210346     Document Type: Review

References (154)

1. Clevers H, Nusse R. Wnt/beta-catenin signaling and disease. Cell 2012; 149: 1192-1205.
2. Nusse R, Varmus H. Three decades of Wnts: a personal perspective on how a scientific field developed. EMBO J 2012; 31: 2670-2684.
3. von Maltzahn J, Chang NC, Bentzinger CF, Rudnicki MA. Wnt signaling in myogenesis. Trends Cell Biol 2012; 22: 602-609.
4. Cossu G, Borello U. Wnt signaling and the activation of myogenesis in mammals. EMBO J 1999; 18: 6867-6872.
5. Tsivitse S. Notch and Wnt signaling, physiological stimuli and postnatal myogenesis. Int J Biol Sci 2010; 6: 268-281.
6. Kharraz Y, Guerra J, Mann CJ, Serrano AL, Munoz-Canoves P. Macrophage plasticity and the role of inflammation in skeletal muscle repair. Mediators Inflamm 2013; 2013: 491-497.
7. Otto A, Schmidt C, Luke G, et al. Canonical Wnt signalling induces satellite-cell proliferation during adult skeletal muscle regeneration. J Cell Sci 2008; 121: 2939-2950.
8. Iglesias DM, Hueber PA, Chu L, et al. Canonical WNT signaling during kidney development. Am J Physiol Renal Physiol 2007; 293: F494-500.
9. Surendran K, McCaul SP, Simon TC. A role for Wnt-4 in renal fibrosis. Am J Physiol Renal Physiol 2002; 282: F431-441.
10. Surendran K, Schiavi S, Hruska KA. Wnt-dependent betacatenin signaling is activated after unilateral ureteral obstruction, and recombinant secreted frizzled-related protein 4 alters the progression of renal fibrosis. J Am Soc Nephrol 2005; 16: 2373-2384.
11. Surendran K, Simon TC. CNP gene expression is activated by Wnt signaling and correlates with Wnt4 expression during renal injury. Am J Physiol Renal Physiol 2003; 284: F653-662.
12. Yoder BK. Role of primary cilia in the pathogenesis of polycystic kidney disease. J Am Soc Nephrol 2007; 18: 1381-1388.
13. Hildebrandt F, Benzing T, Katsanis N. Ciliopathies. N Engl J Med 2011; 364: 1533-1543.
14. Oh EC, Katsanis N. Cilia in vertebrate development and disease. Development 2012; 139: 443-448.
15. Lancaster MA, Gleeson JG. Cystic kidney disease: the role of Wnt signaling. Trends Mol Med 2010; 16: 349-360.
16. Oh EC, Katsanis N. Context-dependent regulation of Wnt signaling through the primary cilium. J Am Soc Nephrol 2013; 24: 10-18.
17. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol 2008, 214: 199-210.
18. Wynn TA. Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest 2007; 117: 524-529.
19. Wynn TA. Fibrosis under arrest. Nat Med 2010; 16: 523-525.
20. Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med 2012; 18: 1028-1040.
21. Wynn TA. Integrating mechanisms of pulmonary fibrosis. J Exp Med 2011; 208: 1339-1350.
22. Zhou L, Lu H. Targeting fibrosis in Duchenne muscular dystrophy. J Neuropathol Exp Neurol 2010; 69: 771-776.
23. Liu L, Carron B, Yee HT, Yie TA, Hajjou M, Rom W. Wnt pathway in pulmonary fibrosis in the bleomycin mouse model. J Environ Pathol Toxicol Oncol 2009; 28: 99-108.
24. Peng H, Cheng ML. The relationship of metallothionein and liver fibrosis. Zhonghua Gan Zang Bing Za Zhi 2008; 16: 78-79.
25. Bitterman PB, Henke CA. Fibroproliferative disorders. Chest 1991; 99: 81S-84S.
26. Wynn TA, Chawla A, Pollard JW. Macrophage biology in development, homeostasis and disease. Nature 2013; 496: 445-455.
27. Huang C, Ogawa R. Fibroproliferative disorders and their mechanobiology. Connect Tissue Res 2012; 53: 187-196.
28. Serrano AL, Munoz-Canoves P. Regulation and dysregulation of fibrosis in skeletal muscle. Exp Cell Res 2010; 316: 3050-3058.
29. Serrano AL, Mann CJ, Vidal B, Ardite E, Perdiguero E, Munoz-Canoves P. Cellular and molecular mechanisms regulating fibrosis in skeletal muscle repair and disease. Curr Top Dev Biol 2011; 96: 167-201.
30. Duffield JS, Lupher M, Thannickal VJ, Wynn TA. Host responses in tissue repair and fibrosis. Annu Rev Pathol 2012; 8: 241-276.
31. Gonzalez AA, Luffman C, Bourgeois CR, Vio CP, Prieto MC. Angiotensin II-independent upregulation of cyclooxygenase-2 by activation of the (Pro)renin receptor in rat renal inner medullary cells. Hypertension 2013; 61: 443-449.
32. Akhurst RJ, Hata A. Targeting the TGFbeta signalling pathway in disease. Nat Rev Drug Discov 2012; 11: 790-811.
33. Choi ME, Ding Y, Kim SI. TGF-beta signaling via TAK1 pathway: role in kidney fibrosis. Semin Nephrol 2012; 32: 244-252.
34. Morales MG, Cabello-Verrugio C, Santander C, Cabrera D, Goldschmeding R, Brandan E. CTGF/CCN-2 overexpression can directly induce features of skeletal muscle dystrophy. J Pathol 2011; 225: 490-501.
35. Cabello-Verrugio C, Cordova G, Salas JD. Angiotensin II: role in skeletal muscle atrophy. Curr Protein Pept Sci 2012; 13: 560-569.
36. Cabello-Verrugio C, Morales MG, Cabrera D, Vio CP, Brandan E. Angiotensin II receptor type 1 blockade decreases CTGF/CCN2-mediated damage and fibrosis in normal and dystrophic skeletal muscles. J Cell Mol Med 2012; 16: 752-764.
37. Lopez-Hernandez FJ, Lopez-Novoa JM. Role of TGF-beta in chronic kidney disease: an integration of tubular, glomerular and vascular effects. Cell Tissue Res 2012; 347: 141-154.
38. Massague J. TGFbeta signalling in context. Nat Rev Mol Cell Biol 2012; 13: 616-630.
39. Massague J. TGF-beta signal transduction. Annu Rev Biochem 1998; 67: 753-791.
40. Attisano L, Labbe E. TGFbeta and Wnt pathway cross-talk. Cancer Metastasis Rev 2004; 23: 53-61.
41. Mezzano V, Cabrera D, Vial C, Brandan E. Constitutively activated dystrophic muscle fibroblasts show a paradoxical response to TGF-beta and CTGF/CCN2. J Cell Commun Signal 2007; 1: 205-217.
42. Vial C, Zuniga LM, Cabello-Verrugio C, Canon P, Fadic R, Brandan E. Skeletal muscle cells express the profibrotic cytokine connective tissue growth factor (CTGF/CCN2), which induces their dedifferentiation. J Cell Physiol 2008; 215: 410-421.
43. Patrakka J, Tryggvason K. New insights into the role of podocytes in proteinuria. Nat Rev Nephrol 2009; 5: 463-468.
44. Herman-Edelstein M, Weinstein T, Gafter U. TGFbeta1-dependent podocyte dysfunction. Curr Opin Nephrol Hypertens 2013; 22: 93-99.
45. Leask A, Abraham DJ. TGF-beta signaling and the fibrotic response. FASEB J 2004; 18: 816-827.
46. Shi-Wen X, Leask A, Abraham D. Regulation and function of connective tissue growth factor/CCN2 in tissue repair, scarring and fibrosis. Cytokine Growth Factor Rev 2008; 19: 133-144.
47. Brigstock DR. Regulation of angiogenesis and endothelial cell function by connective tissue growth factor (CTGF) and cysteine-rich 61 (CYR61). Angiogenesis 2002; 5: 153-165.
48. Chen CC, Lau LF. Functions and mechanisms of action of CCN matricellular proteins. Int J Biochem Cell Biol 2009; 41: 771-783.
49. Yoshida K, Munakata H. Connective tissue growth factor binds to fibronectin through the type I repeat modules and enhances the affinity of fibronectin to fibrin. Biochim Biophys Acta 2007; 1770: 672-680.
50. Abreu JG, Ketpura NI, Reversade B, De Robertis EM. Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-beta. Nat Cell Biol 2002; 4: 599-604.
51. Wahab NA, Weston BS, Mason RM. Connective tissue growth factor CCN2 interacts with and activates the tyrosine kinase receptor TrkA. J Am Soc Nephrol 2005; 16: 340-351.
52. Minamizato T, Sakamoto K, Liu T, et al. CCN3/NOV inhibits BMP-2-induced osteoblast differentiation by interacting with BMP and Notch signaling pathways. Biochem Biophys Res Commun 2007; 354: 567-573.
53. Brandan E, Cabello-Verrugio C, Vial C. Novel regulatory mechanisms for the proteoglycans decorin and biglycan during muscle formation and muscular dystrophy. Matrix Biol 2008; 27: 700-708.
54. Passerini L, Bernasconi P, Baggi F, et al. Fibrogenic cytokines and extent of fibrosis in muscle of dogs with Xlinked golden retriever muscular dystrophy. Neuromuscul Disord 2002; 12: 828-835.
55. Herichova I, Szantoova K. Renin-angiotensin system: upgrade of recent knowledge and perspectives. Endocr Regul 2013; 47: 39-52.
56. Santos PC, Krieger JE, Pereira AC. Renin-angiotensin system, hypertension, and chronic kidney disease: pharmacogenetic implications. J Pharmacol Sci 2012; 120: 77-88.
57. Moon JY, Tanimoto M, Gohda T, et al. Attenuating effect of angiotensin-(1-7) on angiotensin II-mediated NAD(P)H oxidase activation in type 2 diabetic nephropathy of KKA(y)/Ta mice. Am J Physiol Renal Physiol 2011; 300: F1271-1282.
58. Burns WC, Velkoska E, Dean R, Burrell LM, Thomas MC. Angiotensin II mediates epithelial-to-mesenchymal transformation in tubular cells by ANG 1-7/MAS-1-dependent pathways. Am J Physiol Renal Physiol 2009; 299: F585-593.
59. Kiribayashi K, Masaki T, Naito T, et al. Angiotensin II induces fibronectin expression in human peritoneal mesothelial cells via ERK1/2 and p38 MAPK. Kidney Int 2005; 67: 1126-1135.
60. Berry C, Touyz R, Dominiczak AF, Webb RC, Johns DG. Angiotensin receptors: signaling, vascular pathophysiology, and interactions with ceramide. Am J Physiol Heart Circ Physiol 2001; 281: H2337-2365.
61. Noh H, Ha H, Yu MR, Kim YO, Kim JH, Lee HB. Angiotensin II mediates high glucose-induced TGF-beta1 and fibronectin upregulation in HPMC through reactive oxygen species. Perit Dial Int 2005; 25: 38-47.
62. Duman S, Sen S, Duman C, Oreopoulos DG. Effect of valsartan versus lisinopril on peritoneal sclerosis in rats. Int J Artif Organs 2005; 28: 156-163.
63. Cisternas P, Henriquez JP, Brandan E, Inestrosa NC. Wnt Signaling in Skeletal Muscle Dynamics: Myogenesis, Neuromuscular Synapse and Fibrosis. Mol Neurobiol 2014; 49: 574-589.
64. Gordon MD, Nusse R. Wnt signaling: Multiple pathways, multiple receptors, and multiple transcription factors. J Biol Chem 2006; 281: 22429-22433.
65. Niehrs C. The complex world of WNT receptor signalling. Nat Rev Mol Cell Biol 2012; 13: 767-779.
66. Wang HY, Liu T, Malbon CC. Structure-function analysis of Frizzleds. Cell Signal 2006; 18: 934-941.
67. Arrazola MS, Varela-Nallar L, Colombres M, et al. Calcium/calmodulin-dependent protein kinase type IV is a target gene of the Wnt/beta-catenin signaling pathway. J Cell Physiol 2009; 221: 658-667.
68. Fuentealba RA, Farias G, Scheu J, Bronfman M, Marzolo MP, Inestrosa NC. Signal transduction during amyloid-betapeptide neurotoxicity: role in Alzheimer disease. Brain Res Brain Res Rev 2004; 47: 275-289.
69. Hodar C, Assar R, Colombres M, et al. Genome-wide identification of new Wnt/beta-catenin target genes in the human genome using CART method. BMC Genomics 2010; 11: 348.
70. Rosso SB, Sussman D, Wynshaw-Boris A, Salinas PC. Wnt signaling through Dishevelled, Rac and JNK regulates dendritic development. Nat Neurosci 2005; 8: 34-42.
71. Chien AJ, Conrad WH, Moon RT. A Wnt survival guide: from flies to human disease. J Invest Dermatol 2009; 129: 1614-1627.
72. Inestrosa NC, Montecinos-Oliva C, Fuenzalida M. Wnt signaling: role in Alzheimer disease and schizophrenia. J Neuroimmune Pharmacol 2012; 7: 788-807.
73. Toledo EM, Colombres M, Inestrosa NC. Wnt signaling in neuroprotection and stem cell differentiation. Prog Neurobiol 2008; 86: 281-296.
74. Varela-Nallar L, Alfaro IE, Serrano FG, Parodi J, Inestrosa NC. Wingless-type family member 5A (Wnt-5a) stimulates synaptic differentiation and function of glutamatergic synapses. Proc Natl Acad Sci U S A 2010; 107: 21164-21169.
75. Jarvinen TA, Kaariainen M, Jarvinen M, Kalimo H. Muscle strain injuries. Curr Opin Rheumatol 2000; 12: 155-161.
76. Hawke TJ, Garry DJ. Myogenic satellite cells: physiology to molecular biology. J Appl Physiol 2001; 91: 534-551.
77. Charge SB, Rudnicki MA. Cellular and molecular regulation of muscle regeneration. Physiol Rev 2004; 84: 209-238.
78. Garcia-Prat L, Sousa-Victor P, Munoz-Canoves P. Functional dysregulation of stem cells during aging: a focus on skeletal muscle stem cells. FEBS J 2013; 280: 4051-4062.
79. Relaix F, Zammit PS. Satellite cells are essential for skeletal muscle regeneration: the cell on the edge returns centre stage. Development 2012; 139: 2845-2856.
80. Trensz F, Haroun S, Cloutier A, Richter MV, Grenier G. A muscle resident cell population promotes fibrosis in hindlimb skeletal muscles of mdx mice through the Wnt canonical pathway. Am J Physiol Cell Physiol 2010; 299: C939-947.
81. Doyonnas R, LaBarge MA, Sacco A, Charlton C, Blau HM. Hematopoietic contribution to skeletal muscle regeneration by myelomonocytic precursors. Proc Natl Acad Sci U S A 2004; 101: 13507-13512.
82. Le Grand F, Rudnicki M. Satellite and stem cells in muscle growth and repair. Development 2007; 134: 3953-3957.
83. Mann CJ, Perdiguero E, Kharraz Y, et al. Aberrant repair and fibrosis development in skeletal muscle. Skelet Muscle 2011; 1: 21.
84. Wynn TA, Barron L. Macrophages: master regulators of inflammation and fibrosis. Semin Liver Dis 2010; 30: 245-257.
85. Polesskaya A, Seale P, Rudnicki MA. Wnt signaling induces the myogenic specification of resident CD45+ adult stem cells during muscle regeneration. Cell 2003; 113: 841-852.
86. Brack AS, Conboy MJ, Roy S, et al. Increased Wnt signaling during aging alters muscle stem cell fate and increases fibrosis. Science 2007; 317: 807-810.
87. Wei J, Fang F, Lam AP, et al. Wnt/beta-catenin signaling is hyperactivated in systemic sclerosis and induces Smaddependent fibrotic responses in mesenchymal cells. Arthritis Rheum 2012; 64: 2734-2745.
88. Le Grand F, Jones AE, Seale V, Scime A, Rudnicki MA. Wnt7a activates the planar cell polarity pathway to drive the symmetric expansion of satellite stem cells. Cell Stem Cell 2009; 4: 535-547.
89. Otto A, Schmidt C, Patel K. Pax3 and Pax7 expression and regulation in the avian embryo. Anat Embryol (Berl) 2006; 211: 293-310.
90. Brack AS, Conboy IM, Conboy MJ, Shen J, Rando TA. A temporal switch from notch to Wnt signaling in muscle stem cells is necessary for normal adult myogenesis. Cell Stem Cell 2008; 2: 50-59.
91. Ren S, Johnson BG, Kida Y, et al. LRP-6 is a coreceptor for multiple fibrogenic signaling pathways in pericytes and myofibroblasts that are inhibited by DKK-1. Proc Natl Acad Sci U S A 2013; 110: 1440-1445.
92. von Maltzahn J, Renaud JM, Parise G, Rudnicki MA. Wnt7a treatment ameliorates muscular dystrophy. Proc Natl Acad Sci U S A 2012; 109: 20614-20619.
93. Kawakami T, Ren S, Duffield JS. Wnt signalling in kidney diseases: dual roles in renal injury and repair. J Pathol 2013; 229: 221-231.
94. Kato H, Susztak K. Repair problems in podocytes: Wnt, Notch, and glomerulosclerosis. Semin Nephrol 2012; 32: 350-356.
95. Kotchen TA, Cowley AW, Jr., Frohlich ED. Salt in health and disease--a delicate balance. N Engl J Med 2013; 368: 1229-1237.
96. Hovater MB, Sanders PW. Effect of dietary salt on regulation of TGF-beta in the kidney. Semin Nephrol 2012; 32: 269-276.
97. Soros P, Whitehead S, Spence JD, Hachinski V. Antihypertensive treatment can prevent stroke and cognitive decline. Nat Rev Neurol 2013; 9: 174-178.
98. He W, Dai C, Li Y, Zeng G, Monga SP, Liu Y. Wnt/betacatenin signaling promotes renal interstitial fibrosis. J Am Soc Nephrol 2009; 20: 765-776.
99. He W, Tan RJ, Li Y, et al. Matrix metalloproteinase-7 as a surrogate marker predicts renal Wnt/beta-catenin activity in CKD. J Am Soc Nephrol 2012; 23: 294-304.
100. He W, Zhang L, Ni A, et al. Exogenously administered secreted frizzled related protein 2 (Sfrp2) reduces fibrosis and improves cardiac function in a rat model of myocardial infarction. Proc Natl Acad Sci U S A 2010; 107: 21110-21115.
101. Dai C, Stolz DB, Kiss LP, Monga SP, Holzman LB, Liu Y. Wnt/beta-catenin signaling promotes podocyte dysfunction and albuminuria. J Am Soc Nephrol 2009; 20: 1997-2008.
102. Heikkila E, Juhila J, Lassila M, et al. beta-Catenin mediates adriamycin-induced albuminuria and podocyte injury in adult mouse kidneys. Nephrol Dial Transplant 2010; 25: 2437-2446.
103. Lan HY, Chung AC. TGF-beta/Smad signaling in kidney disease. Semin Nephrol 2012; 32: 236-243.
104. Rooney B, O'Donovan H, Gaffney A, et al. CTGF/CCN2 activates canonical Wnt signalling in mesangial cells through LRP6: implications for the pathogenesis of diabetic nephropathy. FEBS Lett 2011; 585: 531-538.
105. Wang Q, Usinger W, Nichols B, et al. Cooperative interaction of CTGF and TGF-beta in animal models of fibrotic disease. Fibrogenesis Tissue Repair 2011; 4: 4.
106. Wuebken A, Schmidt-Ott KM. WNT/beta-catenin signaling in polycystic kidney disease. Kidney Int 2011; 80: 135-138.
107. Isaka Y, Fujiwara Y, Ueda N, Kaneda Y, Kamada T, Imai E. Glomerulosclerosis induced by in vivo transfection of transforming growth factor-beta or platelet-derived growth factor gene into the rat kidney. J Clin Invest 1993; 92: 2597-2601.
108. Mozes MM, Bottinger EP, Jacot TA, Kopp JB. Renal expression of fibrotic matrix proteins and of transforming growth factor-beta (TGF-beta) isoforms in TGF-beta transgenic mice. J Am Soc Nephrol 1999; 10: 271-280.
109. Chiarelli F, Gaspari S, Marcovecchio ML. Role of growth factors in diabetic kidney disease. Horm Metab Res 2009; 41: 585-593.
110. Ziyadeh FN. Different roles for TGF-beta and VEGF in the pathogenesis of the cardinal features of diabetic nephropathy. Diabetes Res Clin Pract 2008; 82 (Suppl 1): S38-41.
111. Liu Y. Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. J Am Soc Nephrol 2004; 15: 1-12.
112. Pulkkinen K, Murugan S, Vainio S. Wnt signaling in kidney development and disease. Organogenesis 2008; 4: 55-59.
113. Kim K, Lu Z, Hay ED. Direct evidence for a role of betacatenin/ LEF-1 signaling pathway in induction of EMT. Cell Biol Int 2002; 26: 463-476.
114. Saadi-Kheddouci S, Berrebi D, Romagnolo B, et al. Early development of polycystic kidney disease in transgenic mice expressing an activated mutant of the beta-catenin gene. Oncogene 2001; 20: 5972-5981.
115. Cadoret A, Ovejero C, Saadi-Kheddouci S, et al. Hepatomegaly in transgenic mice expressing an oncogenic form of beta-catenin. Cancer Res 2001; 61: 3245-3249.
116. Cuevas CA, Tapia-Rojas C, Cespedes C, Inestrosa NC, Vio CP. Wnt/β-catenin signaling pathway participates in renal fibrosis induced in 2K1C Goldblatt hypertensive rats. Plos One 2014; in press.
117. Romaker D, Puetz M, Teschner S, et al. Increased expression of secreted frizzled-related protein 4 in polycystic kidneys. J Am Soc Nephrol 2009; 20: 48-56.
118. Surendran K, Simon TC, Liapis H, McGuire JK. Matrilysin (MMP-7) expression in renal tubular damage: association with Wnt4. Kidney Int 2004; 65: 2212-2222.
119. Jiang L, Xu L, Song Y, et al. Calmodulin-dependent Protein Kinase II/cAMP Response Element-binding Protein/Wnt/beta-Catenin Signaling Cascade Regulates Angiotensin II-induced Podocyte Injury and Albuminuria. J Biol Chem 2013; 288: 23368-23379.
120. Wennmann DO, Hsu HH, Pavenstadt H. The reninangiotensin-aldosterone system in podocytes. Semin Nephrol 2012; 32: 377-384.
121. Harwood L, Wilson B. Genetics and polycystic kidney disease. CANNT J 2004; 14: 37.
122. Wilson PD. Polycystic kidney disease: new understanding in the pathogenesis. Int J Biochem Cell Biol 2004; 36: 1868-1873.
123. Pazour GJ, Dickert BL, Vucica Y, et al. Chlamydomonas IFT88 and its mouse homologue, polycystic kidney disease gene tg737, are required for assembly of cilia and flagella. J Cell Biol 2000; 151: 709-718.
124. Pazour GJ, San Agustin JT, Follit JA, Rosenbaum JL, Witman GB. Polycystin-2 localizes to kidney cilia and the ciliary level is elevated in orpk mice with polycystic kidney disease. Curr Biol 2002; 12: R378-380.
125. Pazour GJ, Baker SA, Deane JA, et al. The intraflagellar transport protein, IFT88, is essential for vertebrate photoreceptor assembly and maintenance. J Cell Biol 2002; 157: 103-113.
126. Berbari NF, Sharma N, Malarkey EB, et al. Microtubule modifications and stability are altered by cilia perturbation and in cystic kidney disease. Cytoskeleton (Hoboken) 2013; 70: 24-31.
127. McIntyre JC, Davis EE, Joiner A, et al. Gene therapy rescues cilia defects and restores olfactory function in a mammalian ciliopathy model. Nat Med 2012; 18: 1423-1428.
128. Lancaster MA, Gleeson JG. The primary cilium as a cellular signaling center: lessons from disease. Curr Opin Genet Dev 2009; 19: 220-229.
129. Pedersen LB, Veland IR, Schroder JM, Christensen ST. Assembly of primary cilia. Dev Dyn 2008; 237: 1993-2006.
130. Ishikawa H, Marshall WF. Ciliogenesis: building the cell's antenna. Nat Rev Mol Cell Biol 2011; 12: 222-234.
131. Singla V, Reiter JF. The primary cilium as the cell's antenna: signaling at a sensory organelle. Science 2006; 313: 629-633.
132. Berbari NF, O'Connor AK, Haycraft CJ, Yoder BK. The primary cilium as a complex signaling center. Curr Biol 2009; 19: R526-535.
133. Luyten A, Su X, Gondela S, et al. Aberrant regulation of planar cell polarity in polycystic kidney disease. J Am Soc Nephrol 2010; 21: 1521-1532.
134. Park TJ, Mitchell BJ, Abitua PB, Kintner C, Wallingford JB. Dishevelled controls apical docking and planar polarization of basal bodies in ciliated epithelial cells. Nat Genet 2008; 40: 871-879.
135. Ross AJ, May-Simera H, Eichers ER, et al. Disruption of Bardet-Biedl syndrome ciliary proteins perturbs planar cell polarity in vertebrates. Nat Genet 2005; 37: 1135-1140.
136. Thoma CR, Frew IJ, Hoerner CR, Montani M, Moch H, Krek W. pVHL and GSK3beta are components of a primary cilium maintenance signalling network. Nat Cell Biol 2007; 9: 588-595.
137. Corbit KC, Shyer AE, Dowdle WE, et al. Kif3a constrains beta-catenin-dependent Wnt signalling through dual ciliary and non-ciliary mechanisms. Nat Cell Biol 2008; 10: 70-76.
138. Gerdes JM, Liu Y, Zaghloul NA, et al. Disruption of the basal body compromises proteasomal function and perturbs intracellular Wnt response. Nat Genet 2007; 39: 1350-1360.
139. Lin F, Hiesberger T, Cordes K, et al. Kidney-specific inactivation of the KIF3A subunit of kinesin-II inhibits renal ciliogenesis and produces polycystic kidney disease. Proc Natl Acad Sci U S A 2003; 100: 5286-5291.
140. Dabdoub A, Donohue MJ, Brennan A, et al. Wnt signaling mediates reorientation of outer hair cell stereociliary bundles in the mammalian cochlea. Development 2003; 130: 2375-2384.
141. May-Simera HL, Kelley MW. Cilia, Wnt signaling, and the cytoskeleton. Cilia 2012; 1: 7.
142. Park TJ, Haigo SL, Wallingford JB. Ciliogenesis defects in embryos lacking inturned or fuzzy function are associated with failure of planar cell polarity and Hedgehog signaling. Nat Genet 2006; 38: 303-311.
143. Zeng H, Hoover AN, Liu A. PCP effector gene Inturned is an important regulator of cilia formation and embryonic development in mammals. Dev Biol 2010; 339: 418-428.
144. Nakaya MA, Biris K, Tsukiyama T, Jaime S, Rawls JA, Yamaguchi TP. Wnt3a links left-right determination with segmentation and anteroposterior axis elongation. Development 2005; 132: 5425-5436.
145. Thoma CR, Frew IJ, Krek W. The VHL tumor suppressor: riding tandem with GSK3beta in primary cilium maintenance. Cell Cycle 2007; 6: 1809-1813.
146. Simons M, Gloy J, Ganner A, et al. Inversin, the gene product mutated in nephronophthisis type II, functions as a molecular switch between Wnt signaling pathways. Nat Genet 2005; 37: 537-543.
147. Otto EA, Schermer B, Obara T, et al. Mutations in INVS encoding inversin cause nephronophthisis type 2, linking renal cystic disease to the function of primary cilia and leftright axis determination. Nat Genet 2003; 34: 413-420.
148. Verkaar F, van Rosmalen JW, Smits JF, Blankesteijn WM, Zaman GJ. Stably overexpressed human Frizzled-2 signals through the beta-catenin pathway and does not activate Ca2+-mobilization in Human Embryonic Kidney 293 cells. Cell Signal 2009; 21: 22-33.
149. von Toerne C, Schmidt C, Adams J, et al. Wnt pathway regulation in chronic renal allograft damage. Am J Transplant 2009; 9: 2223-2239.
150. Vlad A, Rohrs S, Klein-Hitpass L, Muller O. The first five years of the Wnt targetome. Cell Signal 2008; 20: 795-802.
151. Wilson PD. Polycystic kidney disease. N Engl J Med 2004; 350: 151-164.
152. Putoux A, Attie-Bitach T, Martinovic J, Gubler MC. Phenotypic variability of Bardet-Biedl syndrome: focusing on the kidney. Pediatr Nephrol 2012; 27: 7-15.
153. Harris PC. Genetic complexity in Joubert syndrome and related disorders. Kidney Int 2007; 72: 1421-1423.
154. Salonen R, Paavola P. Meckel syndrome. J Med Genet 1998; 35: 497-501.